This report provides a comprehensive analysis of the global cancer biomarker testing market, which is experiencing significant growth driven by the rising incidence of cancer and the increasing demand for precision medicine. The study examines key applications such as early detection, diagnosis, and treatment monitoring, highlighting next-generation sequencing (NGS) platforms as a dominant technology segment. While high testing costs remain a primary market restraint, North America currently leads the industry due to advanced healthcare infrastructure and robust R&D investments.

Executive Overview

Market Size and Growth

The global cancer biomarker testing market reached US$24.86 billion in 2024 and is projected to reach US$67.74 billion by 2033, growing at a CAGR of 11.5% during the forecast period of 2025-2033.

Definition and Functionality

Cancer biomarker testing involves the analysis of biological markers—such as proteins, genes, or other substances produced by cancer cells or by the body in response to cancer—to indicate the presence or progression of cancer.

Primary Applications

• Early Detection: Identifying cancer at its earliest stages.
• Diagnosis: Confirming the presence of malignancy.
• Prognosis Prediction: Determining the likely course of the disease.
• Treatment Monitoring: Assessing the effectiveness of therapeutic interventions.

Clinical Importance

Identifying specific biomarkers enables more personalized treatment plans by ensuring the selection of the most effective therapies. Biomarker testing is essential for enhancing diagnostic accuracy, guiding treatment choices, and monitoring for signs of cancer recurrence.

Market Dynamics

Drivers

• Rising Incidence of Cancer: The increasing global cancer burden is a significant driver. Healthcare systems are prioritizing early detection, personalized treatment, and continuous monitoring.
• Statistical Context: According to the International Agency for Research on Cancer, 1.46 million new lung cancer cases were diagnosed in 2022. Furthermore, new prostate cancer cases are expected to reach 3.13 million in 2025. This rise in cases fuels the demand for diverse biomarkers and precise diagnostic tools.
• Precision Medicine and Targeted Therapy: Biomarker testing facilitates targeted therapies, which reduces trial-and-error treatment methods and minimizes side effects. This is increasingly vital as cancer treatments grow more complex.
• Advancements in Research: The emphasis on precision medicine and advancements in genomic research are making biomarker testing more accessible and effective, encouraging healthcare providers to adopt these tools to tailor patient care.

Restraints

• High Costs of Biomarker Tests: The high price of these tests presents a significant barrier to widespread adoption, particularly in resource-limited settings. The reliance on cutting-edge technologies and specialized expertise drives up costs, making it difficult for budget-constrained healthcare systems to integrate these tests into routine care. This economic barrier limits equitable access to early detection and personalized treatment.

Segment Analysis

The global cancer biomarker testing market is segmented based on the following criteria:

• Test Type
• Product Type
• Cancer Type
• Application
• Region

Next-Generation Sequencing (NGS) Platforms

Next-generation sequencing (NGS) platforms are expected to dominate the market.

• Technology Overview: NGS refers to advanced sequencing technologies that allow for high-throughput, rapid, and cost-effective analysis of entire genomes or targeted regions of interest. In oncology, NGS provides deep insights into the genetic makeup of tumors, enabling precise detection, diagnosis, and treatment strategies.
• Market Position: NGS platforms are poised for dominance due to their unparalleled ability to provide comprehensive genomic insights. Continuous research and the introduction of advanced platforms are improving cancer detection capabilities.
• Key Example: In October 2024, NeoGenomics, Inc. launched its AML Express, an NGS assay designed for rapid and comprehensive genetic profiling for patients with acute myeloid leukemia (AML).
• Clinical Value: These capabilities enhance early detection, prognosis prediction, and treatment response monitoring. The growing demand for precision medicine favors NGS due to its accuracy, scalability, and versatility.

Geographical Analysis

North America

North America is expected to dominate the cancer biomarker testing market, driven by several key factors:

• Infrastructure and R&D: Sophisticated healthcare infrastructure and substantial investments in research and development.
• Technological Integration: High access to cutting-edge technologies, such as Next-Generation Sequencing (NGS) and liquid biopsy, which accelerates clinical integration.
• Industry Presence: A strong presence of leading biotechnology and pharmaceutical companies at the forefront of innovating and commercializing new tests.
• Precision Medicine Focus: A strong emphasis on personalized treatment and precision medicine, which is crucial for tailoring therapies to individual patients.
• Public Health Drivers: Rising cancer incidence combined with increased public awareness and a focus on early detection.

Competitive Landscape

Key Market Players

• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• Guardant Health
• Agilent Technologies, Inc.
• Quanterix
• Exact Sciences Corporation
• QIAGEN
• Takara Bio Inc.

Key Developments

• Illumina, Inc. (August 2024): Received FDA approval for its in vitro diagnostic (IVD) TruSight Oncology (TSO) Comprehensive test and its first two companion diagnostic (CDx) indications.
• Takara Bio USA, Inc. (April 2024): Launched the Shasta Single-Cell System, an automated, high-throughput NGS solution featuring validated chemistries and bioinformatics tools for novel biomarker discovery in oncology research.

Report Information

Value Proposition: Why Purchase the Report?

• Pipeline & Innovations: Reviews clinical trials, product pipelines, and upcoming pharmaceutical advancements.
• Type Performance & Market Positioning: Analyzes product performance and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development.
• Physician Preferences & Health System Impact: Examines provider behaviors and the impact of health system mergers.
• Market Updates & Industry Changes: Covers regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and access strategies.
• Market Entry & Expansion: Identifies optimal strategies for new market entry and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses risks and distribution strategies for efficient delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving healthcare regulations.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift toward value-based pricing and data-driven R&D decision-making.

Report Specifications

• Tables: Approximately 45
• Figures: Approximately 46
• Total Pages: 180

Target Audience (2024)

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

• 1 Methodology and Scope

  • 1.1 Research Methodology

  • 1.2 Research Objective and Scope of the Report

• 2 Definition and Overview

• 3 Executive Summary

  • 3.1 Snippet by Test Type

  • 3.2 Snippet by Product Type

  • 3.3 Snippet by Cancer Type

  • 3.4 Snippet by Application

  • 3.5 Snippet by Region

• 4 Dynamics

  • 4.1 Impacting Factors

    • 4.1.1 Drivers

      • 4.1.1.1 Rising Incidence of Cancer
      • 4.1.1.2 Advances in Genomic and Molecular Research
      • 4.1.1.3 XX

    • 4.1.2 Restraints

      • 4.1.2.1 High Costs of Biomarker Tests
      • 4.1.2.2 Regulatory and Approval Challenges
      • 4.1.2.3 XX

    • 4.1.3 Opportunities

      • 4.1.3.1 Integration of Cancer Biomarker Testing with Liquid Biopsy for Monitoring
      • 4.1.3.2 XX

    • 4.1.4 Impact Analysis

• 5 Strategic Insights and Industry Outlook

  • 5.1 Market Leaders and Pioneers

    • 5.1.1 Emerging Pioneers and Prominent Players

    • 5.1.2 Established leaders with the largest selling Brand

    • 5.1.3 Market leaders with established Product

  • 5.2 CXO Perspectives

  • 5.3 Latest Developments and Breakthroughs

  • 5.4 Case Studies/Ongoing Research

  • 5.5 Regulatory and Reimbursement Landscape

    • 5.5.1 North America

    • 5.5.2 Europe

    • 5.5.3 Asia Pacific

    • 5.5.4 Latin America

    • 5.5.5 Middle East & Africa

  • 5.6 Porter’s Five Force Analysis

  • 5.7 Supply Chain Analysis

  • 5.8 Patent Analysis

  • 5.9 SWOT Analysis

  • 5.10 Unmet Needs and Gaps

  • 5.11 Recommended Strategies for Market Entry and Expansion

  • 5.12 Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts

  • 5.13 Pricing Analysis and Price Dynamics

  • 5.14 Key Opinion Leaders

• 6 By Test Type

  • 6.1 Introduction

    • 6.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type

    • 6.1.2 Market Attractiveness Index, By Test Type

  • 6.2 Genetic Biomarker Testing*

    • 6.2.1 Introduction

    • 6.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 6.3 Protein Biomarker Testing

  • 6.4 Circulating Tumor DNA (ctDNA) Testing

  • 6.5 Polymerase Chain Reaction (PCR)

  • 6.6 Next-Generation Sequencing (NGS)

  • 6.7 Others

• 7 By Product Type

  • 7.1 Introduction

    • 7.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

    • 7.1.2 Market Attractiveness Index, By Product Type

  • 7.2 Instruments*

    • 7.2.1 Introduction

    • 7.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

    • 7.2.3 PCR (Polymerase Chain Reaction) Machines

    • 7.2.4 Next-Generation Sequencing (NGS) Platforms

    • 7.2.5 Mass Spectrometers

    • 7.2.6 ctDNA (Circulating Tumor DNA) Detection Devices

    • 7.2.7 Others

  • 7.3 Kits & Reagents

• 8 By Cancer Type

  • 8.1 Introduction

    • 8.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

    • 8.1.2 Market Attractiveness Index, By Cancer Type

  • 8.2 Lung Cancer*

    • 8.2.1 Introduction

    • 8.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 8.3 Prostate Cancer

  • 8.4 Breast Cancer

  • 8.5 Leukemia

  • 8.6 Others

• 9 By Application

  • 9.1 Introduction

    • 9.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

    • 9.1.2 Market Attractiveness Index, By Application

  • 9.2 Drug Discovery and Development*

    • 9.2.1 Introduction

    • 9.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 9.3 Disease Screening

  • 9.4 Treatment Planning

  • 9.5 Others

• 10 By Region

  • 10.1 Introduction

    • 10.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

    • 10.1.2 Market Attractiveness Index, By Region

  • 10.2 North America

    • 10.2.1 Introduction

    • 10.2.2 Key Region-Specific Dynamics

    • 10.2.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type

    • 10.2.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

    • 10.2.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

    • 10.2.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

    • 10.2.7 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

      • 10.2.7.1 U.S
      • 10.2.7.2 Canada

  • 10.3 Europe

    • 10.3.1 Introduction

    • 10.3.2 Key Region-Specific Dynamics

    • 10.3.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type

    • 10.3.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

    • 10.3.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

    • 10.3.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

    • 10.3.7 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

      • 10.3.7.1 Germany
      • 10.3.7.2 U.K
      • 10.3.7.3 France
      • 10.3.7.4 Spain
      • 10.3.7.5 Italy
      • 10.3.7.6 Rest of Europe

  • 10.4 Latin America

    • 10.4.1 Introduction

    • 10.4.2 Key Region-Specific Dynamics

    • 10.4.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type

    • 10.4.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

    • 10.4.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

    • 10.4.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

    • 10.4.7 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

      • 10.4.7.1 Brazil
      • 10.4.7.2 Mexico
      • 10.4.7.3 Argentina
      • 10.4.7.4 Rest of Latin America

  • 10.5 Asia-Pacific

    • 10.5.1 Introduction

    • 10.5.2 Key Region-Specific Dynamics

    • 10.5.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type

    • 10.5.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

    • 10.5.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

    • 10.5.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

    • 10.5.7 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

      • 10.5.7.1 China
      • 10.5.7.2 India
      • 10.5.7.3 Japan
      • 10.5.7.4 South Korea
      • 10.5.7.5 Rest of Asia-Pacific

  • 10.6 Middle East and Africa

    • 10.6.1 Introduction

    • 10.6.2 Key Region-Specific Dynamics

    • 10.6.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type

    • 10.6.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

    • 10.6.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

    • 10.6.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

• 11 Competitive Landscape

  • 11.1 Competitive Scenario

  • 11.2 Market Positioning/Share Analysis

  • 11.3 Mergers and Acquisitions Analysis

• 12 Company Profiles

  • 12.1 F. Hoffmann-La Roche Ltd*

    • 12.1.1 Company Overview

    • 12.1.2 Product Portfolio

      • 12.1.2.1 Product Description
      • 12.1.2.2 Product Key Performance Indicators (KPIs)
      • 12.1.2.3 Historic and Forecasted Product Sales
      • 12.1.2.4 Product Sales Volume

    • 12.1.3 Financial Overview

      • 12.1.3.1 Company Revenue’s
      • 12.1.3.2 Geographical Revenue Shares
      • 12.1.3.3 Revenue Forecasts

    • 12.1.4 Key Developments

      • 12.1.4.1 Mergers & Acquisitions
      • 12.1.4.2 Key Product Development Activities
      • 12.1.4.3 Regulatory Approvals etc

    • 12.1.5 SWOT Analysis

  • 12.2 Illumina, Inc

  • 12.3 Thermo Fisher Scientific Inc

  • 12.4 Bio-Rad Laboratories, Inc

  • 12.5 Guardant Health

  • 12.6 Agilent Technologies, Inc

  • 12.7 Quanterix

  • 12.8 Exact Sciences Corporation

  • 12.9 QIAGEN

  • 12.10 Takara Bio Inc

• 13 Appendix

  • 13.1 About Us and Services

  • 13.2 Contact Us